ArticleThe international journal of biochemistry & cell biology2012
Lymphocytes from rheumatoid arthritis patients have elevated levels of intracellular peroxiredoxin 2, and a greater frequency of cells with exofacial peroxiredoxin 2, compared with healthy human lymphocytes.
Article in The international journal of biochemistry & cell biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Diagnostic accuracy of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in rheumatoid arthritis: a systematic review and meta-analysis.Clinical and experimental medicine · 2024Pooled it
- Article
- Article
- Serum peroxiredoxin 2 emerges as a predictive biomarker of poor neurological outcome and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a prospective cohort study.Neurosurgical review · 2025Article
- Feasibility of Serum Peroxiredoxin 2 as a Biochemical Indicator for Reflecting Severity and Prognosticating Stroke-Associated Pneumonia, Early Neurological Deterioration and Poor Neurological Outcomes in Acute Supratentorial Intracerebral Hemorrhage: An Observational Analytical Clinical Study.Neuropsychiatric disease and treatment · 2025Article
- Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging.Archives of toxicology · 2023Review
- Surface Phenotype Changes and Increased Response to Oxidative Stress in CD4Biomedicines · 2021Article
- Characterization of extracellular redox enzyme concentrations in response to exercise in humans.Journal of applied physiology (Bethesda, Md. : 1985) · 2019Article
- Molecular interactions at the surface of extracellular vesicles.Seminars in immunopathology · 2018Review
- Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases.Pharmacology & therapeutics · 2016Review
- Clinical Relevance of Biomarkers of Oxidative Stress.Antioxidants & redox signaling · 2015Review
- Cysteine Oxidation Targets Peroxiredoxins 1 and 2 for Exosomal Release through a Novel Mechanism of Redox-Dependent Secretion.Molecular medicine (Cambridge, Mass.) · 2015Article
- Longitudinal study of circulating protein biomarkers in inflammatory bowel disease.Journal of proteomics · 2015Article
- Synovial membrane protein expression differs between juvenile idiopathic arthritis subtypes in early disease.Arthritis research & therapy · 2014Article
- Protein biomarkers in vernix with potential to predict the development of atopic eczema in early childhood.Allergy · 2014Article
- Healthy ageing and depletion of intracellular glutathione influences T cell membrane thioredoxin-1 levels and cytokine secretion.Chemistry Central journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxiredoxin 2 has immune regulatory functions, but its expression in human peripheral blood lymphocytes and levels in extracellular fluid in healthy subjects and rheumatoid arthritis patients are poorly described. In the present study, the median intracellular peroxiredoxin 2 protein content of lymphocytes from rheumatoid arthritis patients was more than two-fold higher compared with healthy subjects' lymphocytes. Intracellular peroxiredoxin 3 levels were similar in healthy and rheumatoid arthritis lymphocytes. Flow cytometry detected peroxiredoxin 2 on the surface of ca. 8% of T cells and ca. 56% of B cells (median % values) of all subjects analyzed. Exofacial thioredoxin-1 was also observed. In the total lymphocyte population from rheumatoid arthritis patients, few cells (median, 6%) displayed surface peroxiredoxin 2. In contrast, a significantly increased proportion of interleukin-17(+ve) lymphocytes were exofacially peroxiredoxin 2(+ve) (median, 39%). Prdx2 was also detected in human extracellular fluids. We suggest that crucial inflammatory cell subsets, i.e. interleukin-17(+ve) T cells, exhibit increased exofacial redox-regulating enzymes and that peroxiredoxin 2 may be involved in the persistence of pro-inflammatory cells in chronic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.